GLP-1 receptor agonists show potential in impacting diseases like Alzheimer's and Parkinson's positively, beyond just treating diabetes and obesity.
Recent research suggests that Parkinson's patients treated with lixisenatide, a diabetes drug, maintained their motor abilities without major changes for a year, indicating promising outcomes.
#glp-1-receptor-agonists #diabetes-treatment #obesity-treatment #alzheimers-disease #parkinsons-disease
[
add
]
[
|
|
...
]